{"id":"zostavax-vaccine","safety":{"commonSideEffects":[{"rate":"48","effect":"Injection site erythema/redness"},{"rate":"41","effect":"Injection site swelling"},{"rate":"34","effect":"Injection site pain/tenderness"},{"rate":"1","effect":"Headache"},{"rate":"1","effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a weakened live strain of varicella-zoster virus that replicates in the body at low levels, triggering both cellular and humoral immune responses. This immune activation enhances the body's ability to recognize and control latent VZV, reducing the risk of reactivation that causes shingles and post-herpetic neuralgia in older adults.","oneSentence":"Zostavax is a live attenuated vaccine that stimulates the immune system to prevent herpes zoster (shingles) by boosting varicella-zoster virus (VZV)-specific cell-mediated immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:49.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"},{"name":"Reduction of post-herpetic neuralgia in patients who develop shingles"}]},"trialDetails":[{"nctId":"NCT06162494","phase":"PHASE4","title":"Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2024-03-18","conditions":"Varicella Zoster","enrollment":80},{"nctId":"NCT07485283","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2026-03","conditions":"Cardiovascular Disease, Dementia","enrollment":162000},{"nctId":"NCT07481604","phase":"PHASE2","title":"Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2026-04","conditions":"Herpes Zoster","enrollment":135},{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT07321808","phase":"","title":"Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2023-05-16","conditions":"Immunocompromised Patients","enrollment":300},{"nctId":"NCT07443709","phase":"PHASE2","title":"Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Oriol Manuel","startDate":"2026-04","conditions":"Zoster; Herpes","enrollment":75},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT05775718","phase":"PHASE2","title":"Shingrix In Recipients of Allogeneic Transplants","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-10-24","conditions":"Bone Marrow Transplant, Stem Cell Transplant","enrollment":55},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT07354659","phase":"PHASE2","title":"Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-01-10","conditions":"Herpes Zoster","enrollment":800},{"nctId":"NCT06932523","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-04-04","conditions":"Herpes Zoster (HZ)","enrollment":645},{"nctId":"NCT07311148","phase":"PHASE2","title":"A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-23","conditions":"Herpes Zoster (HZ), Shingles, VZV","enrollment":840},{"nctId":"NCT02723773","phase":"PHASE3","title":"A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":7539},{"nctId":"NCT04091451","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-09-17","conditions":"Herpes Zoster","enrollment":1430},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT05811754","phase":"","title":"Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-05-09","conditions":"Herpes Zoster","enrollment":2844},{"nctId":"NCT06890416","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-04","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":526},{"nctId":"NCT06569823","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over","status":"RECRUITING","sponsor":"Dynavax Technologies Corporation","startDate":"2024-06-17","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":764},{"nctId":"NCT06605625","phase":"","title":"Vaccine Responses in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-11-04","conditions":"Viral Vaccines","enrollment":250},{"nctId":"NCT05898464","phase":"PHASE4","title":"Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2023-06-27","conditions":"Vaccination; Infection, Vaccine Adverse Reaction","enrollment":150},{"nctId":"NCT07170059","phase":"","title":"Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-10-01","conditions":"Lung Cancer","enrollment":500},{"nctId":"NCT03604406","phase":"PHASE2","title":"The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2014-05-08","conditions":"Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT05575830","phase":"PHASE4","title":"Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Calmy Alexandra","startDate":"2022-12-14","conditions":"RZV Vaccine (Shingrix ®)","enrollment":225},{"nctId":"NCT05701800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-01-23","conditions":"Herpes Zoster","enrollment":659},{"nctId":"NCT06409494","phase":"PHASE1","title":"Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"EuBiologics Co.,Ltd","startDate":"2024-07-15","conditions":"Varicella Zoster Virus Infection, Herpes Zoster","enrollment":72},{"nctId":"NCT05550194","phase":"PHASE4","title":"VZV in the Enteric Nervous System: Pathogenesis and Consequences","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-03-27","conditions":"Achalasia","enrollment":40},{"nctId":"NCT06961721","phase":"PHASE4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-05","conditions":"Prevention of Herpes Zoster","enrollment":600},{"nctId":"NCT03798691","phase":"PHASE4","title":"Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-05-28","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":33},{"nctId":"NCT06874842","phase":"PHASE1","title":"Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older","status":"RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-03-13","conditions":"Herpes Zoster (HZ)","enrollment":92},{"nctId":"NCT05966090","phase":"PHASE3","title":"A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-28","conditions":"Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections","enrollment":530},{"nctId":"NCT06581575","phase":"PHASE2","title":"A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2024-10-16","conditions":"Herpes Zoster (HZ), Infectious Diseases, Shingles","enrollment":467},{"nctId":"NCT06335849","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-03-27","conditions":"Herpes Zoster","enrollment":48},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT06262776","phase":"NA","title":"Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Central Adelaide Local Health Network Incorporated","startDate":"2024-03-20","conditions":"Immunosuppression, Vaccine Response Impaired","enrollment":120},{"nctId":"NCT06801509","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-02-15","conditions":"Herpes Zoster","enrollment":540},{"nctId":"NCT04869982","phase":"PHASE4","title":"Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-14","conditions":"Herpes Zoster","enrollment":6138},{"nctId":"NCT06763783","phase":"PHASE4","title":"Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Region Skane","startDate":"2024-12-17","conditions":"Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis","enrollment":240},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT05991427","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-11-07","conditions":"Herpes Zoster","enrollment":65},{"nctId":"NCT06654700","phase":"PHASE3","title":"Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-12-09","conditions":"Herpes Zoster","enrollment":1200},{"nctId":"NCT05636436","phase":"PHASE1","title":"Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2022-12-07","conditions":"Herpes Zoster","enrollment":132},{"nctId":"NCT05856084","phase":"PHASE2","title":"Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-05-07","conditions":"Herpes Zoster","enrollment":924},{"nctId":"NCT06137755","phase":"PHASE1","title":"Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above","status":"RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2023-03-15","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":32},{"nctId":"NCT06447779","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-07-13","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT04169009","phase":"PHASE4","title":"Persistence of Protection by Shingrix","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-07-28","conditions":"Herpes Zoster","enrollment":105},{"nctId":"NCT06334861","phase":"","title":"Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-06-23","conditions":"Herpes Zoster","enrollment":178},{"nctId":"NCT06224270","phase":"PHASE4","title":"Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2024-10","conditions":"Inflammatory Bowel Diseases, IBD","enrollment":""},{"nctId":"NCT05871541","phase":"PHASE1","title":"A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine","status":"COMPLETED","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2023-05-26","conditions":"Herpes Zoster (HZ), Shingles, Infectious Disease","enrollment":75},{"nctId":"NCT06592456","phase":"PHASE3","title":"A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-07-21","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT04748939","phase":"PHASE4","title":"Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT","status":"NOT_YET_RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2025-01","conditions":"Herpes Zoster","enrollment":140},{"nctId":"NCT04047979","phase":"PHASE2","title":"Systems Biology of Zoster Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-14","conditions":"Zoster, Zoster Varicella, Shingles","enrollment":38},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06364033","phase":"NA","title":"Biological and Clinical Efficacy of Shingrix in Patients With CLL","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2024-08","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL-like MBL","enrollment":312},{"nctId":"NCT02735915","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-11","conditions":"Herpes Zoster","enrollment":70},{"nctId":"NCT05596526","phase":"PHASE4","title":"Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients","status":"RECRUITING","sponsor":"Prof Patrice Lalive","startDate":"2022-12-01","conditions":"Shingles, Zoster","enrollment":100},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT03771157","phase":"EARLY_PHASE1","title":"Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-02-01","conditions":"Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)","enrollment":33},{"nctId":"NCT05924685","phase":"PHASE4","title":"PREPARE-iVAC Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2023-08-22","conditions":"COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response","enrollment":110},{"nctId":"NCT05769049","phase":"PHASE1","title":"The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)","status":"COMPLETED","sponsor":"Jiangsu Rec-Biotechnology Co., Ltd.","startDate":"2023-02-09","conditions":"Herpes Zoster","enrollment":48},{"nctId":"NCT03993717","phase":"","title":"Solid Organ Transplant SHINGRIX","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-01-30","conditions":"Kidney Transplant; Complications","enrollment":2},{"nctId":"NCT04089930","phase":"","title":"Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2020-06-01","conditions":"Lupus Erythematosus","enrollment":68},{"nctId":"NCT05371080","phase":"PHASE3","title":"A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-08-10","conditions":"Herpes Zoster","enrollment":3038},{"nctId":"NCT04072497","phase":"PHASE1, PHASE2","title":"A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-20","conditions":"Herpes Zoster","enrollment":522},{"nctId":"NCT01911065","phase":"PHASE4","title":"T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Herpes Zoster","enrollment":54},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT04523246","phase":"EARLY_PHASE1","title":"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2020-09-01","conditions":"Herpes Zoster, Allergy and Immunology, Corona Virus Infection","enrollment":217},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT06088745","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine","status":"RECRUITING","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-09-28","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":4},{"nctId":"NCT03702231","phase":"PHASE2","title":"Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL)","enrollment":116},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":"Influenza, Herpes Zoster","enrollment":148},{"nctId":"NCT05750017","phase":"PHASE1","title":"A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-03-23","conditions":"Herpes Zoster, Vaccine-Preventable Diseases","enrollment":66},{"nctId":"NCT05554068","phase":"PHASE2","title":"Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","status":"RECRUITING","sponsor":"Loyola University","startDate":"2023-03-07","conditions":"Shingles","enrollment":100},{"nctId":"NCT05718037","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2023-08-01","conditions":"Herpes Zoster","enrollment":40},{"nctId":"NCT05705180","phase":"","title":"The Influence of Trained Immunity in COVID-19 Vaccinated Individuals","status":"UNKNOWN","sponsor":"Wuerzburg University Hospital","startDate":"2022-12-01","conditions":"Zoster Varicella, Vaccination; Infection","enrollment":600},{"nctId":"NCT05245838","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2022-01-10","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":150},{"nctId":"NCT04516408","phase":"NA","title":"Recombinant Zoster Vaccine in Stable SLE Patients","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-04-20","conditions":"Herpes Zoster, Recombinant Zoster Vaccine, Systemic Lupus Erythematosus","enrollment":464},{"nctId":"NCT01600079","phase":"","title":"ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-15","conditions":"Herpes Zoster, Shingles","enrollment":1505647},{"nctId":"NCT00940940","phase":"PHASE4","title":"Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2009-10","conditions":"Kidney Transplant","enrollment":4},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT03439657","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-12","conditions":"Herpes Zoster","enrollment":913},{"nctId":"NCT04334577","phase":"PHASE3","title":"Study on Efficacy of Attenuated Zoster Vaccine, Live","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2020-04-20","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT02538341","phase":"PHASE2","title":"Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2016-05","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis","enrollment":617},{"nctId":"NCT00851786","phase":"PHASE2","title":"Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-04-29","conditions":"Herpes Zoster, HIV Infections","enrollment":395},{"nctId":"NCT00001125","phase":"PHASE1","title":"Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Chickenpox","enrollment":60},{"nctId":"NCT00000837","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":127},{"nctId":"NCT00681031","phase":"PHASE4","title":"Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05-14","conditions":"Herpes Zoster","enrollment":96},{"nctId":"NCT01262300","phase":"PHASE1","title":"Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11","conditions":"Immunosenescence, Shingles","enrollment":33},{"nctId":"NCT02075515","phase":"PHASE3","title":"Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-13","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":651},{"nctId":"NCT02045836","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-05","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":865},{"nctId":"NCT01798056","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-06","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":237},{"nctId":"NCT02690207","phase":"PHASE3","title":"Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-16","conditions":"Herpes Zoster","enrollment":8687},{"nctId":"NCT01165177","phase":"PHASE3","title":"Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-02","conditions":"Herpes Zoster","enrollment":16165},{"nctId":"NCT03493776","phase":"PHASE4","title":"Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation","status":"UNKNOWN","sponsor":"Deepali Kumar","startDate":"2018-04-15","conditions":"Varicella Zoster Vaccine","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ZOSTAVAX® (Zoster Vaccine Live)"],"phase":"marketed","status":"active","brandName":"Zostavax vaccine","genericName":"Zostavax vaccine","companyName":"Oklahoma Medical Research Foundation","companyId":"oklahoma-medical-research-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zostavax is a live attenuated vaccine that stimulates the immune system to prevent herpes zoster (shingles) by boosting varicella-zoster virus (VZV)-specific cell-mediated immunity. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Reduction of post-herpetic neuralgia in patients who develop shingles.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}